Honey
Phase 3Small molecule
Honey is one of 47 small molecule programs targeting Oxidative Stress. It is currently in Phase 3.
2
Indications
7
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Honey
SSohaib Ashraf
Phase 3
COVID-19 Vaccine
ModernaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Activella
Eli LillyPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-192 trials
Dry Socket1 trial
Oxidative Stress1 trial
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
Completed·—·Phase 2/3·NCT04292314·350 enrolled
Povidone Iodine1 trial
ESS1 trial
Compare Effects of Dressing With Honey and EUSOL
Completed·—·N/A·NCT04831112·326 enrolled
1 more indication
Healing1 trial
Effect of Honey and Dexamethason on Extraction Healing
Completed·—·Phase 1·NCT04848259·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Honey. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSohaib Ashraf